Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.
Victoria P WerthRichard A FurieJuanita Romero-DiazSandra NavarraKenneth KalunianRonald F van VollenhovenFilippa NybergBenjamin H KaffenbergerSaira Z SheikhGoran RadunovicXiaobi HuangGeorge ClarkHua CarrollHimanshu NaikFrancois GaudreaultAdam MeyersCatherine BarbeyCristina MusselliNathalie Franchimontnull nullPublished in: The New England journal of medicine (2022)
In a phase 2 trial involving participants with cutaneous lupus erythematosus, treatment with litifilimab was superior to placebo with regard to a measure of skin disease activity over a period of 16 weeks. Larger and longer trials are needed to determine the effect and safety of litifilimab for the treatment of cutaneous lupus erythematosus. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.).